Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using Brosimum gaudichaudii.

Martins FS, Sy SKB, Fonseca MJV, de Freitas O.

Planta Med. 2020 Mar;86(4):276-283. doi: 10.1055/a-1087-8374. Epub 2020 Jan 22.

PMID:
31968379
2.

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective.

Oo C, Sy SKB.

Drug Discov Today. 2020 Jan;25(1):1-3. doi: 10.1016/j.drudis.2019.07.012. Epub 2019 Sep 6. No abstract available.

PMID:
31499189
3.

Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information.

Menegucci TC, Fedrigo NH, Lodi FG, Albiero J, Nishiyama SAB, Mazucheli J, Carrara-Marroni FE, Voelkner NMF, Gong H, Sy SKB, Tognim MCB.

Microb Drug Resist. 2019 Nov;25(9):1266-1274. doi: 10.1089/mdr.2018.0283. Epub 2019 Jun 19.

PMID:
31216222
4.

Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.

Albiero J, Mazucheli J, Barros JPDR, Szczerepa MMDA, Nishiyama SAB, Carrara-Marroni FE, Sy S, Fidler M, Sy SKB, Tognim MCB.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00126-19. doi: 10.1128/AAC.00126-19. Print 2019 Jun.

5.

Physiologically-based pharmacokinetics of ziprasidone in pregnant women.

Biesdorf C, Martins FS, Sy SKB, Diniz A.

Br J Clin Pharmacol. 2019 May;85(5):914-923. doi: 10.1111/bcp.13872. Epub 2019 Mar 11.

PMID:
30669177
6.

A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.

Sy SKB, Zhuang L, Xia H, Schuck VJ, Nichols WW, Derendorf H.

Clin Microbiol Infect. 2019 Jul;25(7):904.e9-904.e16. doi: 10.1016/j.cmi.2018.10.014. Epub 2018 Oct 28.

PMID:
30394361
7.

Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.

Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SKB, Rand KH, Peloquin CA, Louie A, Derendorf H.

Int J Antimicrob Agents. 2019 Mar;53(3):275-283. doi: 10.1016/j.ijantimicag.2018.10.012. Epub 2018 Oct 29.

PMID:
30385322
8.

Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Sy SKB, Zhuang L, Sy S, Derendorf H.

Clin Pharmacokinet. 2019 May;58(5):545-564. doi: 10.1007/s40262-018-0705-y. Review.

PMID:
30097887
9.

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.

Sy SKB, Chia YL, Gordi T, Hoch U, Eldon MA.

Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21.

10.

Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.

Zhu P, Sy SKB, Skerjanec A.

AAPS J. 2018 Mar 7;20(2):40. doi: 10.1208/s12248-018-0196-7.

PMID:
29516330
11.

A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.

Sy SKB, Zhuang L, Xia H, Beaudoin ME, Schuck VJ, Nichols WW, Derendorf H.

J Antimicrob Chemother. 2018 May 1;73(5):1295-1304. doi: 10.1093/jac/dkx537.

PMID:
29415212
12.

Fixed-dose combinations: a potential means to boost drug development for selected drugs.

Oo C, Sy SKB.

Drug Discov Today. 2018 Mar;23(3):457-459. doi: 10.1016/j.drudis.2017.11.001. Epub 2017 Nov 14. No abstract available.

PMID:
29146518
13.

Dermal pharmacokinetics of pyrazinamide determined by microdialysis sampling in rats.

Voelkner NMF, Voelkner A, Costa J, Sy SKB, Hermes J, Weitzel J, Morales S, Derendorf H.

Int J Antimicrob Agents. 2018 Feb;51(2):190-196. doi: 10.1016/j.ijantimicag.2017.10.001. Epub 2017 Oct 13.

PMID:
29032112
14.

Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations.

Sy SKB, Derendorf H.

Clin Microbiol Infect. 2018 Jul;24(7):707-715. doi: 10.1016/j.cmi.2017.07.020. Epub 2017 Jul 29.

15.

Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.

Fedrigo NH, Mazucheli J, Albiero J, Shinohara DR, Lodi FG, Machado ACDS, Sy SKB, Tognim MCB.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e02498-16. doi: 10.1128/AAC.02498-16. Print 2017 Aug.

16.

Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice.

Li SS, Ip CK, Tang MY, Sy SK, Yung S, Chan TM, Yang M, Shum HC, Wong AS.

J Vis Exp. 2017 Feb 18;(120). doi: 10.3791/55337.

17.

Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.

Sy SK, Zhuang L, Beaudoin ME, Kircher P, Tabosa MA, Cavalcanti NC, Grunwitz C, Pieper S, Schuck VJ, Nichols WW, Derendorf H.

J Antimicrob Chemother. 2017 Apr 1;72(4):1109-1117. doi: 10.1093/jac/dkw535.

PMID:
28077672
18.

Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.

Sy SK, Sweeney TD, Ji C, Hoch U, Eldon MA.

Cancer Chemother Pharmacol. 2017 Jan;79(1):57-67. doi: 10.1007/s00280-016-3192-6. Epub 2016 Nov 30.

19.

Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.

Yu M, Gao Z, Dai X, Gong H, Zhang L, Chen X, Zhong DF, Sy SK.

Clin Pharmacokinet. 2017 Jan;56(1):65-76. doi: 10.1007/s40262-016-0427-y.

PMID:
27379402
20.

Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress.

Ip CK, Li SS, Tang MY, Sy SK, Ren Y, Shum HC, Wong AS.

Sci Rep. 2016 Jun 1;6:26788. doi: 10.1038/srep26788.

21.

Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.

Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, Tognim MC.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4128-39. doi: 10.1128/AAC.03099-15. Print 2016 Jul.

22.

Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.

Shilbayeh SA, Sy SK, Melhem M, Zmeili R, Derendorf H.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):387-94. doi: 10.1002/cpdd.172. Epub 2015 Jan 12.

PMID:
27137148
23.

In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.

Sy SK, Beaudoin ME, Zhuang L, Löblein KI, Lux C, Kissel M, Tremmel R, Frank C, Strasser S, Heuberger JA, Mulder MB, Schuck VJ, Derendorf H.

J Antimicrob Chemother. 2016 Jul;71(7):1866-80. doi: 10.1093/jac/dkw082. Epub 2016 Apr 21.

PMID:
27107096
24.

Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model.

Zhuang L, He Y, Xia H, Liu Y, Sy SK, Derendorf H.

J Antimicrob Chemother. 2016 Apr;71(4):1012-21. doi: 10.1093/jac/dkv428. Epub 2015 Dec 24.

PMID:
26702923
25.

Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.

Sy SK, Zhuang L, Derendorf H.

Expert Opin Drug Metab Toxicol. 2016;12(1):93-114. doi: 10.1517/17425255.2016.1123250. Epub 2015 Dec 14. Review.

PMID:
26652832
26.

Rapid and efficient method for the quantification of lychnopholide in rat plasma by liquid chromatography-tandem mass spectrometry for pharmacokinetic application.

Lachi-Silva L, Sousa JPB, Montanha MC, Sy SKB, Lopes JLC, Silva DB, Lopes NP, Diniz A, Kimura E.

Biomed Chromatogr. 2016 Jul;30(7):1092-1096. doi: 10.1002/bmc.3654. Epub 2016 Jan 3.

PMID:
26577838
27.

Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model.

Lachi-Silva L, Sy SK, Voelkner A, de Sousa JP, Lopes JL, Silva DB, Lopes NP, Kimura E, Derendorf H, Diniz A.

Planta Med. 2015 Aug;81(12-13):1121-7. doi: 10.1055/s-0035-1546214. Epub 2015 Jul 28.

PMID:
26218336
28.

N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR.

Antimicrob Agents Chemother. 2015 Jul;59(7):4129-38. doi: 10.1128/AAC.04049-14. Epub 2015 May 11.

29.

Pharmacokinetic evaluation of avicularin using a model-based development approach.

Buqui GA, Gouvea DR, Sy SK, Voelkner A, Singh RS, da Silva DB, Kimura E, Derendorf H, Lopes NP, Diniz A.

Planta Med. 2015 Mar;81(5):373-81. doi: 10.1055/s-0035-1545728. Epub 2015 Mar 17.

PMID:
25782034
30.

Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Sy SK, Malmberg R, Matsushima A, Asin-Prieto E, Rosenkranz B, Cotton MF, Derendorf H, Innes S.

Int J Antimicrob Agents. 2015 Apr;45(4):413-9. doi: 10.1016/j.ijantimicag.2014.12.016. Epub 2015 Jan 19.

31.

Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.

Zhuang L, Sy SK, Xia H, Singh RP, Mulder MB, Liu C, Derendorf H.

Int J Antimicrob Agents. 2015 Feb;45(2):151-60. doi: 10.1016/j.ijantimicag.2014.09.017. Epub 2014 Nov 1.

PMID:
25465523
32.

Predicting pediatric age-matched weight and body mass index.

Sy SK, Asin-Prieto E, Derendorf H, Samara E.

AAPS J. 2014 Nov;16(6):1372-9. doi: 10.1208/s12248-014-9657-9. Epub 2014 Aug 26.

33.

Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR.

Antimicrob Agents Chemother. 2014 Oct;58(10):6242-50. doi: 10.1128/AAC.03073-14. Epub 2014 Aug 11.

34.

Largazole pharmacokinetics in rats by LC-MS/MS.

Yu M, Salvador LA, Sy SK, Tang Y, Singh RS, Chen QY, Liu Y, Hong J, Derendorf H, Luesch H.

Mar Drugs. 2014 Mar 20;12(3):1623-40. doi: 10.3390/md12031623.

35.

Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.

Sy SK, Innes S, Derendorf H, Cotton MF, Rosenkranz B.

Antimicrob Agents Chemother. 2014;58(2):1084-91. doi: 10.1128/AAC.01717-13. Epub 2013 Dec 2.

36.

A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.

Sy SK, Heuberger J, Shilbayeh S, Conrado DJ, Derendorf H.

AAPS J. 2013 Oct;15(4):1189-99. doi: 10.1208/s12248-013-9528-9. Epub 2013 Aug 30.

37.

Electroencephalogram effects of armodafinil: comparison with behavioral alertness.

Conrado DJ, Bewernitz M, Ding M, Cibula J, Seubert C, Sy SK, Eisenschenk S, Derendorf H.

J Clin Pharmacol. 2013 Oct;53(10):1058-71. doi: 10.1002/jcph.143. Epub 2013 Aug 1.

38.

Influence of CYP3A5 6986A > G and ABCB1 3435C > T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients.

Sy SK, Singh RP, Shilbayeh S, Zmeili R, Conrado D, Derendorf H.

Clin Pharmacol Drug Dev. 2013 Jan;2(1):67-78. doi: 10.1002/cpdd.22. Epub 2013 Mar 7.

PMID:
27121561
39.

In silico labeling reveals the time-dependent label half-life and transit-time in dynamical systems.

Maiwald T, Blumberg J, Raue A, Hengl S, Schilling M, Sy SK, Becker V, Klingmüller U, Timmer J.

BMC Syst Biol. 2012 Feb 27;6:13. doi: 10.1186/1752-0509-6-13.

40.

Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk.

Salman S, Sy SK, Ilett KF, Page-Sharp M, Paech MJ.

Eur J Clin Pharmacol. 2011 Sep;67(9):899-908. doi: 10.1007/s00228-011-1023-6. Epub 2011 Mar 11.

PMID:
21394525
41.

Use of a sparse sampling study design to assess transfer of tramadol and its O-desmethyl metabolite into transitional breast milk.

Ilett KF, Paech MJ, Page-Sharp M, Sy SK, Kristensen JH, Goy R, Chua S, Christmas T, Scott KL.

Br J Clin Pharmacol. 2008 May;65(5):661-6. doi: 10.1111/j.1365-2125.2008.03117.x. Epub 2008 Feb 20.

42.
43.

The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.

Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL.

Am J Cardiovasc Drugs. 2003;3(2):101-12.

PMID:
14727937
44.

Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations.

Shi G, Lloyd TL, Sy SK, Jiao Q, Wernicki A, Mutlib A, Emm TA, Unger SE, Pieniaszek HJ Jr.

J Pharm Biomed Anal. 2003 Apr 1;31(5):937-51.

PMID:
12684106
45.

Mulitvariate cluster analysis of a human hepatic cytochrome P450 database.

Sy SK, Johnston JA, Class CF, Roberts EA, Kalow W, Tang BK.

Eur J Clin Pharmacol. 2002 Nov;58(8):559-62. No abstract available.

PMID:
12536990
46.

Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression.

Sy SK, Ciaccia A, Li W, Roberts EA, Okey A, Kalow W, Tang BK.

Eur J Clin Pharmacol. 2002 Aug;58(5):357-65. Epub 2002 Jul 13.

PMID:
12185560
47.
48.

Supplemental Content

Support Center